scholarly journals Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

2018 ◽  
pp. 1-5 ◽  
Author(s):  
Sonia Brugnara ◽  
Mariacristina Sicher ◽  
Elena Maria Bonandini ◽  
Davide Donner ◽  
Franca Chierichetti ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Complete Response ◽  
Metastatic Malignant Melanoma ◽  
Treatment Cessation

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 ◽  
Vol 9 (8) ◽  
pp. 1403-1408 ◽  
Author(s):  
C I Falkson ◽  
G Falkson ◽  
H C Falkson
Keyword(s):  
Malignant Melanoma ◽  
Treatment Failure ◽  
Partial Remission ◽  
Performance Status ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Time To Treatment Failure ◽  
Metastatic Sites

Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

1995 ◽  
Vol 13 (12) ◽  
pp. 2895-2899 ◽  
Author(s):  
A Y Bedikian ◽  
G R Weiss ◽  
S S Legha ◽  
H A Burris ◽  
J R Eckardt ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Complete Response ◽  
Metastatic Malignant Melanoma ◽  
Fluid Retention ◽  
Maximal Response ◽  
Hematologic Toxicity ◽  
Hypersensitivity Reactions ◽  
Cutaneous Toxicity ◽  
Cutaneous Toxicities

PURPOSE A phase II study was undertaken to determine the efficacy of docetaxel in patients with metastatic malignant melanoma. PATIENTS AND METHODS Between June 1992 and March 1994, 40 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg/m2 administered intravenously over 1 hour every 21 days. None of the patients had brain metastasis. Toxicity and follow-up data are provided. RESULTS One patient had a histologically confirmed complete response that lasted for 14+ months. Four patients had partial responses, bringing the overall response rate to 12.5% (95% confidence interval [CI], 6% to 30%). A patient with a partial response had a single chest-wall metastasis and was rendered free of disease surgically after a maximal response to docetaxel and remained free of tumor recurrence after 18+ months. Tumor was stabilized in 22 patients. The overall median survival time was 13 months. The main hematologic toxicity was neutropenia, which was severe but transient. Peripheral neuropathy was the limiting nonhematologic toxicity in three patients. Other important toxicities included cutaneous toxicity, fluid retention, oral mucositis, and hypersensitivity reactions. Preadministration of dexamethasone and diphenhydramine reduced the incidence of hypersensitivity reactions, cutaneous toxicities, and fluid retention. CONCLUSION Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be conducted in multidrug combination programs.

Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070)

2007 ◽  
Vol 17 (5) ◽  
pp. 329-331 ◽  
Author(s):  
Martina Baur ◽  
Margit Gneist ◽  
Takashi Owa ◽  
Christian Dittrich
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma

scholarly journals A 60-Year-Old Female With Metastatic Malignant Melanoma of the Scalp Responding to Ipilimumab

2018 ◽  
Vol 4 ◽  
pp. 2513826X1775111
Author(s):  
Sarah Lohrenz ◽  
Jennifer Crawford ◽  
Shawki Souf
Keyword(s):  
Malignant Melanoma ◽  
Treatment Options ◽  
Poor Response ◽  
Metastatic Malignant Melanoma ◽  
Advanced Stage ◽  
Free Response ◽  
First Case ◽  
Promising Treatment ◽  
Novel Concept

Melanoma is an aggressive disease that accounts for approximately 75% of skin cancer-related deaths. In the past, treatment options for patients with advanced stage melanoma have been limited with poor response rate and failure to improve overall survival (OS). Immunotherapy is a promising treatment that has been shown to improve OS and in cases produce durable remissions—a novel concept in the treatment of advanced melanoma. We report a case of advanced stage metastatic malignant melanoma of the scalp with a durable (31 months) response to ipilimumab immunotherapy. This is the first case study reporting long-term, progression-free response to ipilimumab in metastatic melanoma without side effects of therapy. This case adds to the evidence supporting early referral and initiation of ipilimumab in patients who can tolerate it, with the goal of producing a sustained treatment-free response and preserved quality of life.

51 20-year long-term results of the use of external beam radiotherapy for primary advanced, recurrent and metastatic malignant melanoma

1997 ◽  
Vol 39 (2) ◽  
pp. 160
Author(s):  
M.Heinrich Seegenschmiedt ◽  
Ludwig Keilholz ◽  
Annelore Altendorf-Hofmann ◽  
Hermann Schell ◽  
Christian Wittekind ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
External Beam Radiotherapy ◽  
Metastatic Malignant Melanoma ◽  
Long Term Results ◽  
External Beam

Metastatic Malignant Melanoma of the Gallbladder Presenting as Biliary Colic: A Case Report and Review of Literature

2007 ◽  
Vol 73 (8) ◽  
pp. 833-835 ◽  
Author(s):  
Justin K. Nelms ◽  
Jitesh A. Patel ◽  
Donald P. Atkinson ◽  
John J. Raves
Keyword(s):  
Malignant Melanoma ◽  
Abdominal Ultrasound ◽  
Metastatic Malignant Melanoma ◽  
Biliary Colic ◽  
Review Of Literature ◽  
Term Survival ◽  
Metastatic Lesions ◽  
Common Cancer ◽  
Melanoma Metastases

Malignant melanoma (MM) is the most common cancer to metastasize to the gastrointestinal tract. Autopsy reports estimate that up to 15 per cent of these patients also have gallbladder metastases, and MM accounts for up to 60 per cent of metastatic lesions to the gallbladder. However, despite its prevalence, MM to the gallbladder is reported only sparingly in the literature. This discordance may be explained by the fact that these lesions are seldom symptomatic. Abdominal ultrasound remains the modality of choice in studying gallbladder pathology and has the ability to define metastatic lesions. The effect of screening for gallbladder metastases on improving survival is not well defined, and thus its role remains controversial. Cholecystectomy for melanoma metastases to the gallbladder seems to be mostly palliative, although there have been isolated reports of excellent long-term survival outcomes. The role for immunotherapy and chemotherapy in this population is not well defined, and overall prognosis is poor. Recent reports have advocated laparoscopic cholecystectomy as the treatment of choice, though there remains a concern for peritoneal port site seeding. We present the case of a 48-year-old man with MM metastatic to the gallbladder and a brief review of the literature.

Sign in / Sign up

Export Citation Format

Share Document